



IFW

Docket No. ARC 3061 R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michel Cormier et al.

Serial No. : 10/674,626

Art Unit: 1614

Filed : September 29, 2003

Examiner: To be Assigned

For : Drug Delivery Device and Method Having Coated
Microprojections Incorporating Vasoconstrictors

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 4, 2004
(Date of Deposit)

JOLANTA PENCE

Jolanta Pence

Jolanta Pence
(Signature)

August 4, 2004
(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e)
(attached); or
- ☐ Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ARC3061R1. This form is submitted in triplicate.


Respectfully submitted,

DATED: *August 4, 2004*



David Abraham
Reg. No. 39,554
Attorney for Applicants

Alza Corporation c/o
Johnson & Johnson
One Johnson & Johnson Plaza, WH3221
New Brunswick, NJ 08933-7003
Tel. (650) 564-2498
Fax. (650) 564-2195
Customer No.: 27777



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/674,626
Filing Date	September 29, 2003
First Named Inventor	Michel Cormier
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ARC 3061

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number (if known)	Kind Code ²	
		ALZA Corporation	10/045,842		
		ALZA Corporation	10/099,604		
		ALZA Corporation	60/276,762		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
			Office ³	Number ⁴	KCode ⁵		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		International Search Report dated April 7, 2004 for corresponding Appln. No. PCT/US03/30761	

Examiner
SignatureDate
Considered

Substitute for form 1449A-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 3	Application Number	10/674,626
	Filing Date	September 28, 2003
	First Named Inventor	M. Cormier et al.
	Group Art Unit	1614
	Examiner Name	Not yet assigned
	Attorney Docket Number	ARC 3061 R1

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
	AT	EP	0 407 063 A1	A1	Connaught Laboratories Limited	01/09/1991		
	AU	WO	93/17754		Elan Medical Technologies Limited	09/16/1993		
	AV	WO	96/17648		Cibageigy AG	06/13/1996		
	AW	WO	96/37155		Silicon Microdevices, Inc.	11/28/1996		
	AX	WO	96/37156		Issa Muta	11/28/1996		
	AY	WO	97/03718		Boehringer Ingelheim KG	02/06/1997		
	AZ	WO	97/48440		ALZA Corporation	12/24/1997		
	BA	WO	97/48441		ALZA Corporation	12/24/1997		
	BB	WO	97/48442		ALZA Corporation	12/24/1997		
	BC	WO	98/00193		Altea Technologies, Inc.	01/08/1998		
	BD	WO	98/28037		ALZA Corporation	07/02/1998		
	BE	WO	98/29298		Shell Internationale Research Maatschappij B. V.	07/09/1998		
	BF	WO	98/29365		BASF Aktiengesellschaft	07/09/1998		
	BG	WO	99/64580		Georgia Tech Research Corporation	12/16/1999		
	BH	WO	02/074173	A1	ALZA Corporation	09/26/2002		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.